American Capital Advisory’s Cytokinetics CYTK Stock Holding History
Bought
Maintained
Sold
Other funds holding CYTK
ACA
American Capital Advisory's CYTK Position: Q2 2026 in Review
American Capital Advisory opened a new position in Cytokinetics (CYTK) in Q2 2026: 1 share worth $86. The stake represents ﹤0.01% of the portfolio and ranks #1135 among its holdings. This is a return to the name: American Capital Advisory previously reported a position in CYTK as recently as Q1 2025.
American Capital Advisory first reported a position in CYTK in Q1 2025 and has held it in 2 quarters since. The position peaked at $201 in Q1 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.
- American Capital Advisory held 1 share of Cytokinetics worth $86 as of Q2 2026.
- Cytokinetics was a new American Capital Advisory position in Q2 2026.
- Cytokinetics made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #1135 holding.
- American Capital Advisory first reported a position in Cytokinetics in Q1 2025 and has held it in 2 quarters since.
- American Capital Advisory's Cytokinetics position peaked at $201 in Q1 2025.
- 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.
Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.